 "Natco Pharma surges as US court invalidates Teva's Copaxone patent")
Shares of Natco Pharma has surged 6% to Rs 2,204 on the BSE after a US appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version.
“U.S. Court of Appeals for Federal Circuit has again found Teva’s U S Patent No. 5,800,808 (‘the 808 patent”) for Copaxone to be invalid as indefinite,” Natco Pharma said in press release.
The company awaits United States Food and Drug Administration (USFDA) approval to launch the product, it added.
The 2-1 decision by the US Court of Appeals for the Federal Circuit, the nation's top patent tribunal, was a blow to Israel's Teva in its seven-year fight against two generic drugmakers over the patent protections for Copaxone, the Reuters report suggests. CLICK HERE TO READ REPORT.
The stock opened at Rs 2,098 and touched high of Rs 2,240 on the BSE. A combined 230,000 shares changed hands on the counter on the BSE and NSE till 1155 hours.
“U.S. Court of Appeals for Federal Circuit has again found Teva’s U S Patent No. 5,800,808 (‘the 808 patent”) for Copaxone to be invalid as indefinite,” Natco Pharma said in press release.
The company awaits United States Food and Drug Administration (USFDA) approval to launch the product, it added.
The 2-1 decision by the US Court of Appeals for the Federal Circuit, the nation's top patent tribunal, was a blow to Israel's Teva in its seven-year fight against two generic drugmakers over the patent protections for Copaxone, the Reuters report suggests. CLICK HERE TO READ REPORT.
The stock opened at Rs 2,098 and touched high of Rs 2,240 on the BSE. A combined 230,000 shares changed hands on the counter on the BSE and NSE till 1155 hours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%